1 / 29

Hemoglobinopathies

Hemoglobinopathies. Diseases affecting the structure, function or production of Hb. Types. 1- Structural Hemoglobinopathies A- Abnormal Hb polymerization --- Sickle cell anemia B- Altered O2 affinity --- High affinity – polycythemia

coy
Télécharger la présentation

Hemoglobinopathies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hemoglobinopathies Diseases affecting the structure, function or production of Hb.

  2. Types 1-Structural Hemoglobinopathies A- Abnormal Hb polymerization --- Sickle cell anemia B- Altered O2 affinity --- High affinity – polycythemia --- Low affinity – Cyanosis, pseudo anemia C- Hb that oxidize readily --- Unstable Hb (HA, jaundice) --- MetHb (cyanosis)

  3. 2- Thalassemia (defective biosynthesis of globin chains) A- α-thalassemia B- β-thalassemia C- δβ, γδβ, αβ thalassemias

  4. 3- Thalassemic Hb variants (structurally abnormal Hb associated with co-inherited thalassemic phenotype) A- Hb-E B- Hb - Constant spring C- Hb- Lepore

  5. 4- Hereditary persistence of fetal Hb (HPHF) (Hb F in adults)

  6. 5- Acquired Hemoglobinopathies A- Met-Hb due to toxic exposure. B- Sulf-Hb due to toxic exposure. C- CarboxyHb due to CO. D- Hb-H in erythroleukemia. E- Elevated Hb-F in states of erythroid stress & BM dysplasia.

  7. Thalassemia This is an inherited disorder of α or β globin chain biosynthesis. Causes reduced production of Hb tetramers causing hypochromia &microcytosis. The latter is leading to ineffective erythropoiesis & hemolytic anemia. Normal Hb consists of 2α and 2β chains. Two clusters of genes encode for globin synthesis (β genes on chromosome 11 & α genes on chromosome 16). An unbalanced accumulation of α or β chains results

  8. α- Thalassemia Decreased α-chain production relative to β-chain production forming β4 (Hb-H inclusion bodies). RBCs bearing inclusion bodies are rapidly removed from the circulation by RES cells thus shortening RBC survival.

  9. S & S Deletion of 1 gene (-α/αα) & 2 genes (-/αα; -α/-α) are virtually asymptomatic. Deletion of 3 genes (--/-α) producing Hb H disease (Hb Barts). Moderate hypochromic microcytic anemia & splenomegaly. Hb= 8-10 g/dL, special stain shows Hb H inclusions. Hb electrophoresis shows Hb H. Hb H tends to precipitate during oxidative stress & under increased temperature as in infections causing hemolysis.

  10. Deletion of 4 genes (--/--) is the most severe form that is incompatible with life leading to intrauterine death of the fetus (hydrops fetalis).

  11. β- Thalassemia Decrease in β-chain production relative to α-chain production. Common in Mediterranean, Asian & African populations (areas endemic with malaria). Trait --- asymptomatic. Clinical anemia ---- is seen in homozygous or compoundheterozygous e.g. β thalassemia/Hb E.

  12. Reduced β globin chain synthesis leads to accumulation of free α globin chains that precipitate in early erythroblast development since they are insoluble. These lead to ineffective erythropoiesis in BM & enhanced destruction in circulation.

  13. Anemia, splenomegaly ± hypersplenism, osteoporosis, skeletal & soft tissue changes due to BM expansion, ironoverload ( ↑GIT absorption & blood transfusion) deposit in liver, heart, pancreas, pituitary & other endocrine organs.

  14. Lab. Dx Microcytic hypochromic anemia, MCV ↓. Hb- electrophoresis --- Hb A2 ↑ > 4-6%, Hb F ↑ 5-20%. PCR, DNA probes. Antenatal Dx --- Amniotic fluid analysis & chorionic villous sampling.

  15. ℞ α-thalassemia ---- 1 gene or 2 genes deletion may be asymptomatic and require no treatment. Hb H disease- Folic acid 1mg/day orally Splenectomy for progressive anemia.

  16. β thalassemia Improved outcome recently due to the use of aggressive blood transfusion support & effective iron chelation therapy. The only curative ttt by BM transplantation.

  17. Blood transfusion – non-transfused pt survives only 2 y in homozygous state. -- Aim to maintain Hb at 11-13g/dL -- Pre-transfusion level>10g/dL -- extend life to 2nd decade, minimize bony abnormalities, and improve sexual development. -- Leukocyte-poor RBCs given to minimize allosenstization & not to prejudice future BMT. -- HB vaccine given for pt with –ve Ab test

  18. Splenectomy if transfusion requirement > 1.5 normal (>200ml/kg/year) -- preceded by polyvalent pneumococcal vaccine (pediatric pt also given H influenza & N meningitides vaccine)

  19. Iron chelation --- if not given pts will die of iron overload. --- Subcutaneous desferrioxamine 1.5-2.5 g/d --- Oral defroperone, deferasirox --- S.C desferral 12-24 h infusion 5-6x/w --- S/E visual disturbances, tinnitus, azotemia, proteinuria. Annual ophth & audiol exam needed.

  20. --- Periodic estimation of iron burden (S Fe, TIBC & S Ferritin) --- Estimate of liver iron concentration --- Annual cardiac evaluation to detect early dis --- GTT, thyroid function test, cortisol determination --- Hormone replacement therapy

  21. Stem cell transplant Allogeneic BMT for homozygous β thalassemia

  22. Manipulation of globin chain gene expression with 5-azacytidine, hydroxyurea, erythropoietin, butyrate analogues to stimulate Hb F synthesis by γ globin chain augmentation

  23. Experimental ttt --- gene therapy * For β globin alleles * Still investigational

More Related